Search

Displaying results 3861 - 3870 of 7063 in total
  1. Drug

    Muromonab

    go.drugbank.com/drugs/DB00075
    ApprovedInvestigationalWithdrawn

    Muromonab is 93% monomeric immune globulin G type 2a (IgG2a). … More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method.

  2. Drug

    Alogliptin

    go.drugbank.com/drugs/DB06203
    ApprovedInvestigational

    FDA approved January 25, 2013. … Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4).

  3. Drug

    Cannabidivarin

    go.drugbank.com/drugs/DB14050
    Investigational

    Desensitization of these ion channels is a potential mechanism by which these molecules cause a reduction of neuronal hyperexcitability that contributes to epileptic activity and seizures. … Cannabidivarin, also known as cannabidivarol or CBDV, is a non-psychoactive cannabinoid found within [DB14009].

  4. Drug

    Berdazimer

    go.drugbank.com/drugs/DB18712
    Approved

    This decision is based on positive results demonstrated in 2 Phase 3 trials, B-SIMPLE 4 and B-SIMPLE 2, where reduced lesion counts were observed with once-a-day uses of berdazimer.[L49520] … Berdazimer is a polymeric substance consisting of a polysiloxane backbone (Si-O-Si bonds) with covalently bound N-diazeniumdiolate nitric oxide (NO) donors.

  5. Drug

    Potassium gluconate

    go.drugbank.com/drugs/DB13620
    Approved

    Potassium gluconate is a salt of [DB01345] and is classified as a food additive by the FDA [L2654]. It is also used as a potassium supplement [L2657]. Potassium is an essential nutrient. … It is the most abundant cation in the intracellular fluid, where it plays a key role in maintaining cell function [A32222].

    Synonyms: potassium D-gluconate
  6. Drug

    Vorasidenib

    go.drugbank.com/drugs/DB17097
    ApprovedInvestigational

    [A264209] It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2 isoforms. … [A264209] Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.[L51144]

  7. Drug

    Tebentafusp

    go.drugbank.com/drugs/DB15283
    ApprovedInvestigational

    to be approved by the FDA. … [L39995] It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs), a recently developed cancer immunotherapy with a novel mechanism

  8. Drug

    Gantenerumab

    go.drugbank.com/drugs/DB12034
    Investigational

    Gantenerumab binds to a unique Aβ epitope compared to other anti-Aβ antibodies and preferentially recognizes Aβ oligomers and fibrils over monomers.[A244720] … Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological hallmarks including extracellular amyloid-beta (Aβ) plaques and intraneuronal neurofibrillary

  9. Drug

    Paroxetine

    go.drugbank.com/drugs/DB00715
    ApprovedInvestigational

    Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. … [T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.

    Products: PAROXETIN 1A PHARMA 10MG, PAROXETIN 1A PHARMA 20MG
  10. Drug

    Etripamil

    go.drugbank.com/drugs/DB12605
    ApprovedInvestigational

    Etripamil is a nondihydropyridine, L-type calcium channel blocker.[A275238, L54728] It is a fast-acting drug with a short duration of action. … [A275243, A275248] The nasal formulation of etripamil was first approved by the FDA on December 12, 2025 for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT